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Behavioral/Systems/Cognitive
Central Opioid Inhibition of Neuroendocrine Stress
Responses in Pregnancy in the Rat Is Induced by the
Neurosteroid Allopregnanolone
Paula J. Brunton,1 Ailsa J. McKay,1 Tomasz Oche˛dalski,2 Agnieszka Piastowska,2 Elz˙bieta Re˛bas,3
Agnieszka Lachowicz,†2 and John A. Russell1
1Laboratory of Neuroendocrinology, Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom, and Departments
of 2Comparative Endocrinology and 3Molecular Neurochemistry, Medical University of Ło´dz´, 91-425 Ło´dz´, Poland
Thehypothalamus–pituitary–adrenal (HPA) axis is themajor neuroendocrine stress response system. Corticotropin-releasing hormone
(CRH) neurons in the parvocellular paraventricular nucleus (pPVN) play a key role in coordinating responses of this system to stressors.
The cytokine interleukin-1 (IL-1), mimicking infection, robustly activates these CRH neurons via a noradrenergic input arising from
the nucleus tractus solitarii (NTS). In late pregnancy, HPA axis responses to stressors, including IL-1, are attenuated by a central opioid
mechanism that auto-inhibits noradrenaline release in the PVN. Here we show that the neuroactive progesterone metabolite allopreg-
nanolone induces these changes in HPA responsiveness to IL-1 in pregnancy. In late pregnancy, inhibition of 5-reductase (an
allopregnanolone-synthesizing enzyme) with finasteride restored HPA axis responses (rapidly increased pPVN CRHmRNA expression,
ACTH, and corticosterone secretion) to IL-1. Conversely, allopregnanolone reduced HPA responses in virgin rats. In late pregnancy,
activity of the allopregnanolone-synthesizing enzymes (5-reductase and 3-hydroxysteroid dehydrogenase) was increased in the
hypothalamus as was mRNA expression in the NTS and PVN. Naloxone, an opioid antagonist, restores HPA axis responses to IL-1 in
pregnancy but had no additional effect after finasteride, indicating a causal connection between allopregnanolone and the endogenous
opioid mechanism. Indeed, allopregnanolone induced opioid inhibition over HPA responses to IL-1 in virgin rats. Furthermore, in
virgin rats, allopregnanolone treatment increased,whereas in pregnant rats finasteride decreased proenkephalin-AmRNAexpression in
the NTS. Thus, in pregnancy, allopregnanolone induces opioid inhibition over HPA axis responses to immune challenge. This novel
opioid-mediated mechanism of allopregnanolone action may alter regulation of other brain systems in pregnancy.
Introduction
The brain activates the endocrine response to acute stress
through multiple stressor processing pathways that converge
onto corticotropin-releasing hormone (CRH) neurons in the
parvocellular paraventricular nucleus (pPVN) of the hypothala-
mus (Buller et al., 2001; Choi et al., 2007). During stress, these
neurons release CRH into the hypothalamo-hypophysial portal
system, stimulating ACTH secretion from anterior pituitary cor-
ticotrophs, which drives glucocorticoid (corticosterone) synthe-
sis and secretion by the adrenal cortex. Administration of the
cytokine interleukin-1 (IL-1), to mimic infection, robustly
stimulates this hierarchical hypothalamus–pituitary–adrenal
(HPA) axis (Buller et al., 2001; Brunton et al., 2005). IL-1 acti-
vates pPVN CRH neurons via a direct noradrenergic pathway
from the nucleus tractus solitarii (NTS) (Rivier et al., 1989). Cir-
culating IL-1 binds to IL-1 receptors on brain microvessel en-
dothelium, triggering local prostaglandin synthesis (Zhang and
Rivest, 1999; Rivest et al., 2000), which excites PVN-projecting
noradrenergic A2 neurons (Ericsson et al., 1994).
In late pregnancy, reduced activation of pPVN CRH neurons
by stressors leads to attenuated ACTH and corticosterone re-
sponses (Brunton et al., 2008). This adaptationmay be important
in altered metabolic and immune balance in pregnancy and in
protecting fetuses from adverse programming (Brunton and
Russell, 2008). In late pregnant rats, HPA axis responses to sys-
temic IL-1 are essentially absent, through inhibition by an
emergent endogenous opioid mechanism (Brunton et al., 2005).
Systemic IL-1 still activates NTS neurons in pregnancy, but
opioid acting presynaptically blocks IL-1-induced noradrena-
line release in the PVN (Brunton et al., 2005). The source of the
opioid peptide and receptor is evidently the NTS neurons that
Received Feb. 6, 2009; revised April 8, 2009; accepted April 9, 2009.
This work was supported by the Biotechnology and Biological Sciences Research Council, British Council, by
Medical University of Ło´dz´ Grants 502-19-681 and 502-11-581, and by Ministry of Science and Higher Education
Grant N404-1077-33 (Poland). We thank Helen Cameron (University of Edinburgh, Edinburgh, UK) for technical
assistance. Undergraduate students Joanne Halfacre, Catherine Harrison, and Stella Howgate assisted in some
experiments. Prof. Marcel Karperien and Dr. Jakomijn Hoogendam (University of Leiden, Leiden, The Netherlands)
provided the plasmid containing 5-reductase cDNA, and Prof. Trevor Penning (University of Pennsylvania, Phila-
delphia, PA) provided the plasmid containing 3-hydroxysteroid dehydrogenase cDNA. Prof. Vladimir Patchev
(Jenapharm, Jena, Germany) gave technical advice on 3-hydroxysteroid dehydrogenase in situ hybridization.
Protein measurements were performed at the Medical University of Ło´dz´. Dr. Martin Simmen and Prof. Gareth Leng
(University of Edinburgh) provided expert advice on performing the statistical analyses. This paper is dedicated to
the memory of Prof. Agnieszka Lachowicz (1961–2008).
†Deceased, May 27, 2008.
Correspondence should be addressed to Paula J. Brunton, Centre for Integrative Physiology, Hugh Robson Build-
ing, George Square, University of Edinburgh, Edinburgh EH8 9XD, UK. E-mail: p.j.brunton@ed.ac.uk.
DOI:10.1523/JNEUROSCI.0708-09.2009
Copyright © 2009 Society for Neuroscience 0270-6474/09/296449-12$15.00/0
The Journal of Neuroscience, May 20, 2009 • 29(20):6449 – 6460 • 6449
project to the PVN: mRNA expression for proenkephalin-A
(pENK-A) and the -opioid receptor (MOR) is increased in the
NTS A2 region in late pregnancy (Brunton et al., 2005).
Here we sought to identify the pregnancy signal that in-
duces opioid inhibition of the HPA axis. The female sex ste-
roids estradiol and progesterone are produced in increasing
amounts in pregnancy, but mimicking their pregnancy levels
in virgin rats does not attenuate HPA axis stress responses
(Douglas et al., 2000). However, allopregnanolone (3,5-
tetrahydroprogesterone or 5-pregnan-3-ol-20-one) (AP),
the neuroactive steroid metabolite of progesterone, is abun-
dant in the brain in pregnancy and can reduce stress-induced
HPA axis activity in male rats (Concas et al., 1998). Allopreg-
nanolone is produced by sequential action of 5-reductase
and 3-hydroxysteroid dehydrogenase (3-HSD), which are
both expressed in the brain (Compagnone and Mellon, 2000).
As well as allosterically modulating GABAA receptors, to en-
hance the effectiveness of GABA actions (Herd et al., 2007),
allopregnanolone can also modulate neuropeptide gene ex-
pression (Bali and Kova´cs, 2003).
Here, we investigate a role for allopregnanolone in restraining
HPA axis responses to IL-1 in late pregnancy by inhibiting allo-
pregnanolone synthesis in late pregnant rats and by measuring
HPA responses to IL-1 in nonpregnant rats treated with allo-
pregnanolone. Furthermore, we test whether activity and gene
expression of the allopregnanolone synthesizing enzymes are in-
creased centrally in late pregnancy. Moreover, we seek evidence
that allopregnanolone is involved in the induction and mainte-
nance of the inhibitory opioid mechanism that emerges in
pregnancy.
Materials andMethods
Animals. Female Sprague Dawley rats (initial body weight, 240–290 g;
Charles River Laboratories) were housed under standard conditions of
temperature (20–22°C) and lighting (12 h light/dark cycle, lights on at
7:00 A.M.) with food and water available ad libitum. Rats were initially
housed in groups of five to six for 3 weeks and then caged individually
after surgery. Pregnant rats were obtained by mating overnight with a
sexually experienced male, and the pregnancy was confirmed by finding
a vaginal plug of semen on the floor of the breeding cage the following
morning (day 1 of pregnancy; day 22 is the expected day of parturition).
Virgin rats selected at random stages of the estrus cycle were used as
controls. The number of rats per group for each experiment is given in
the figure legends. All procedures were performed in accordance with
current United Kingdom Home Office regulations and with University
of Edinburgh Ethical Committee approval.
Surgery: jugular vein cannulation. Changes in ACTH and corticoste-
rone secretion were assessed by collecting serial venous blood samples.
Five days before the experiment, virgin and day 16 pregnant rats were
fitted with a SILASTIC jugular vein cannula (wall, 0.25 mm; internal
diameter, 0.5 mm; filled with sterile heparinized 0.9% saline, 50 U/ml)
under inhalational halothane anesthesia (2–3% halothane, in 1200 ml/
min oxygen) for subsequent blood sampling and drug administration.
Blood sampling and tissue collection.On themorning of the experiment
(between 7:30and 9:00A.M.), the jugular cannulawas connected to poly-
vinyl chloride extension tubing (wall, 1 mm; internal diameter, 0.5 mm)
filled with heparinized saline (50 U/ml 0.9% saline) and attached to a 1
ml syringe, for remote sampling. Rats were then left undisturbed for 90
min. After collection of two basal blood samples (at t  31 and 1
min), rats were administered 500 ng/kg human recombinant IL-1 in-
travenously (1 g/ml; dissolved in 0.2% bovine serum albumin in PBS;
t 0 min; R & D Systems). Additional blood samples were taken 15, 30,
60, 90, and 120 min after treatment. Blood samples (0.35 ml) were col-
lected into 1ml syringes containing 20l of 5%EDTA, chilled on ice, and
centrifuged to separate plasma, which was frozen and stored at 20°C
until assay. Each blood sample was replaced immediately with an equiv-
alent volume of warmed sterile 0.9% saline. Rats were killed by conscious
decapitation 4 h after IL-1 injection [the optimum time point for de-
tecting peak changes in CRH mRNA expression after exposure to stress
(Harbuz and Lightman, 1989)]. Trunk blood was collected into tubes
containing chilled 5%EDTA (0.2ml/100 g bodyweight), and plasmawas
separated and stored as above. Brains were rapidly removed, frozen on
dry ice, and stored at70°Cuntil sectioning. CRHneuron activationwas
evaluated by quantitative in situ hybridization (ISH) for CRH mRNA
(see below). Pregnancy status was checked postmortem, and only preg-
nant rats with at least six viable fetuses were included in the study (actual
range, 6–17 pups; mode, 14 pups).
Experiment 1: is allopregnanolone involved in suppressing HPA axis re-
sponses in pregnant rats? To investigate a role for allopregnanolone in
suppressed HPA axis responses to IL-1 in late pregnancy, allopreg-
nanolone productionwas blocked using finasteride (5-reductase inhib-
itor). Blood samples and brains were collected (as above) from virgin and
pregnant (day 21) rats treated with either finasteride (25 mg/kg, s.c.;
Steraloids) or vehicle (15% ethanol in sesame oil; 0.5 ml/kg) 20 and 2 h
before IL-1 (t20 and2 h). A separate group of pregnant (day 21)
rats were treated with finasteride or vehicle (as above) only (no IL-1).
Such finasteride treatment reduces brain allopregnanolone content by
90% in pregnant and 77% in nonpregnant rats, to similar actual levels
(Concas et al., 1998).
Experiment 2: can the effects of pregnancy on HPA axis responses be
mimicked in virgin rats with allopregnanolone treatment? To test whether
suppressedHPA axis responses to IL-1 could bemimicked in virgin rats
with allopregnanolone treatment, blood samples and brains were col-
lected from virgin rats treated with AP (3 and 1 mg/kg, s.c., 20 and 2 h
before IL-1, respectively; Steraloids) or vehicle (15%ethanol in corn oil;
0.5 ml/kg). To verify that the effects of finasteride on HPA responses to
IL-1 seen in pregnant rats were attributable to the actions of allopreg-
nanolone, blood samples and brains were also collected from pregnant
(day 20–21) rats treated with finasteride (as before) and either allopreg-
nanolone or vehicle (as above).
Experiment 3: can the allopregnanolone precursors suppress HPA axis
responses in virgin rats? To establish whether administration of the allo-
pregnanolone precursors progesterone or dihydroprogesterone (DHP)
can restrain HPA axis responses to IL-1, virgin rats were treated with
progesterone (20 and 4mg/kg, s.c., 20 and 2 h before IL-1, respectively;
Steraloids) or vehicle (10% benzyl alcohol and 0.3% cresol in arachis oil;
0.5 ml/kg). A separate set of rats were treated with dihydroprogesterone
(4 and 1 mg/kg, s.c. 20 and 2 h before IL-1, respectively; Steraloids) or
vehicle (15% benzyl alcohol and 0.3% cresol in arachis oil; 0.5 ml/kg). In
both cases, blood and brains were collected to evaluate HPA axis activity.
Experiment 4: does the expression of mRNAs for the allopregnanolone-
synthesizing enzymes increase in the brain during pregnancy?To investigate
whethermRNA expression for 5-reductase and/or 3-HSD is increased
in the brain in pregnancy, untreated virgin and pregnant (day 21) rats
were killed by conscious decapitation. Brains, brainstems, and liver (pos-
itive control) were removed, frozen on dry ice, and stored at70°C until
processing for ISH.
Experiment 5: are the activities of the allopregnanolone-synthesizing en-
zymes increased in the brain during pregnancy? To investigate whether the
activity of 5-reductase and/or 3-HSD is increased in the brain in preg-
nancy, untreated virgin and pregnant (day 21) rats were killed by con-
scious decapitation. Brains were removed, and the hypothalamus (cut
rostrocaudally between the optic chiasm and mammillary bodies, later-
ally at the hypothalamic sulci and dorsally below the ventral thalamus)
andmedulla oblongata [bregma,10 to15mm (Paxinos andWatson,
1998)] were dissected, frozen on dry ice, and stored at70°C until sub-
sequent enzyme assay.
Experiment 6: are the effects of allopregnanolone and endogenous opioids
in pregnant rats interdependent? Pregnant rats (day 21) were pretreated
with either vehicle or finasteride (as before). Immediately after the first
basal blood sample was collected, rats were given either naloxone [5
mg/kg, i.v.; naloxone was used at this dose as a nonselective opioid re-
ceptor antagonist, as before (Brunton et al., 2005), because the opioid
receptor type that mediates opioid inhibition of HPA axis in pregnancy
has not been defined] or vehicle (0.9% saline, 0.5 ml/kg). After an addi-
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tional two blood samples 15 and 30min later, all rats were given IL-1 (as
before). Additional blood samples were taken 15, 30, 60, 90, and 120min
after IL-1, rats were killed at 4 h (as before), and brains were collected to
assess CRH neuron activation by quantitative ISH for CRHmRNA. One
group of control virgin rats were given oil vehicle and saline pretreatment
before IL-1 and sampled as above. Separate groups of virgin and preg-
nant rats were blood sampled after treatment with only naloxone (i.e.,
with no subsequent IL-1 treatment) or saline.
Experiment 7: can allopregnanolone induce opioid inhibition over HPA
axis responses in virgin rats?To establish whether allopregnanolone exerts
its effects on HPA responsiveness by inducing inhibitory opioid tone,
virgin rats were given either allopregnanolone or vehicle (as before).
Immediately after the first basal blood sample was taken, rats were given
either naloxone (5 mg/kg, i.v.) or vehicle (0.9% saline, 0.5 ml/kg). After
an additional two blood samples 15 and 30 min later, all rats were given
IL-1 (as before). Additional blood samples were taken 15, 30, 60, 90,
and 120 min after IL-1, rats were killed at 4 h (as before), and brains
were collected to assess CRH neuron activation by quantitative ISH for
CRH mRNA.
Experiment 8: does allopregnanolone alter central opioid expression? To
investigate whether allopregnanolone upregulates central opioid expres-
sion virgin rats were treated with allopregnanolone or vehicle (as in
experiment 2). Late pregnant rats were treated with finasteride or vehicle
(as in experiment 1). Two hours after the second injection, rats were
killed by conscious decapitation. Expression of pENK-A, pro-
opiomelanocortin (POMC), and MOR mRNAs in selected nuclei in the
hypothalamus and brainstem were evaluated by quantitative ISH.
Radioimmunoassays.ACTH concentrations were determined in unex-
tracted plasma using a commercially available two-site immunoradio-
metric kit (Euro-diagnostica), whereas corticosterone (IDS Ltd.) and
progesterone (Diagnostic Systems Laboratories) were measured using
radioimmunoassay kits. The sensitivity and intra-assay variation for each
of the assays were as follows: ACTH: sensitivity, 1 pg/ml and intra-assay
variation, 7%; corticosterone: sensitivity, 0.4 ng/ml and intra-assay
variation8%; progesterone: sensitivity, 0.3 ng/ml and intra-assay vari-
ation6%. All samples from any one experiment were assayed together.
In situ hybridization.Tissue was sectioned coronally on a cryostat at 15
m and thawmounted onto Polysine slides. All sections from a particu-
lar experiment were processed in the same hybridization reaction. 35S-
Radiolabeled oligonucleotide probes (MWG-Biotech) were used to de-
tect CRH, pENK-A, POMC, and -opioid receptor mRNA expression.
The sequences of each oligonucleotide probe are given in Table 1 and in
situ hybridization using these probes was performed as described previ-
ously (Brunton et al., 2005).
[ 35S]UTP-labeled cRNA sense and antisense probes were synthesized
from the linearized pBluescript SK vector expressing a 344 bp (nucle-
otides 991–1334) cDNA fragment encoding rat 5-reductase type I [the
predominant isoform expressed in adult brain (Compagnone and Mel-
lon, 2000; Sa´nchez et al., 2008a,b); generously provided by Prof. Marcel
Karperien, Leiden UniversityMedical Center, Leiden, The Netherlands].
The plasmid was linearized withXhoI andXbaI and transcribed using T3
and T7 polymerase (Promega) for the sense and antisense riboprobes,
respectively. To detect 3-HSDmRNA, [ 35S]UTP-labeled sense and an-
tisense riboprobes were generated from the linearized pGEM3 vector
expressing a 982 bp (nucleotides129 to853) cDNA fragment encod-
ing rat 3-HSD (generously provided by Prof. Trevor Penning, Univer-
sity of Pennsylvania, Philadelphia, PA). The plasmid was linearized with
SalI and SspI, and sense and antisense cRNAs incorporating [ 35S]UTP
were transcribed from the T7 and SP6 promoters, respectively.
For in situ hybridization using riboprobes, tissue was first fixed in 4%
paraformaldehyde, acetylated in triethanol-
amine/acetic anhydride solution, and then par-
tially dehydrated in ethanol before incubation
in prehybridization buffer [50% deionized for-
mamide (v/v), 1 Denhardt’s solution, 1 mM
EDTA, 0.5 mg/ml salmon testes DNA, 600 mM
sodium chloride, 10 mM Tris, and 125 g/ml
yeast tRNA] at 50°C for 120 min. Riboprobes
incorporating 35S-labeled UTP were mixed
with hybridization buffer [50% deionized for-
mamide (v/v), 1 Denhardt’s solution, 10% dextran sulfate (w/v), 15
mM dithiothreitol, 1 mM EDTA, 0.1 mg/ml salmon testes DNA, 600 mM
sodium chloride, 10 mM Tris, and 125 g/ml yeast tRNA], heated for 10
min at 70°C, quenched on ice, and applied to the tissue (650,000 cpm/
section). To aid tissue penetration, the radiolabeled 3-HSD riboprobe
was fragmented by alkaline hydrolysis and neutralized before hybridiza-
tion. Sections were hybridized at 55°C and 60°C (for 5-reductase and
3-HSD mRNAs, respectively) for 18–19 h. Sections of rat liver treated
as abovewere used as positive controls. Brain and liver sections serving as
negative controls to ensure probe specificity were hybridized with
[ 35S]UTP-labeled cRNA sense probes. The hybridization signal over tis-
sue hybridized with the sense probe was not different from background.
After hybridization, the slides were rinsed briefly (to remove cover-
slips) in 2 SSC and then washed three times for 5 min in 2 SSC at
room temperature. Next, sectionswere incubated in buffer (1mMEDTA,
500mM sodium chloride, and 10mMTris) containing 15g/ml RNase A
for 60 min at 37°C. Sections were then briefly rinsed in 2 SSC at room
temperature before additional stringency washing (for 5-reductase,
once in 2 SSC at 37°C and twice at 55°C for 30 min each, followed by
two 60min washes in 0.2 SSC at 55°C; and for 3-HSD, 60min each in
2 SSC at 50°C and in 0.2 SSC at 55°C and then 60°C). After the
posthybridizationwashes, tissuewas dehydrated in an ascending series of
ethanol containing 300 mM ammonium acetate, air dried, dipped in
autoradiographic emulsion (Ilford K-5), and exposed at 4°C. Exposure
times for each mRNA species were as follows: CRH, 10 weeks; 3-HSD,
10weeks; pENK-A, 6weeks; POMC, 5weeks;-opioid receptor, 6weeks;
and 5-reductase, 7 weeks.
Slides were developed (KodakD-19; Sigma), fixed (Hypam rapid fixer;
Ilford), and counterstained with hematoxylin and eosin. Autoradio-
graphs were quantified using three methods. (1) The area of each region
of interest (e.g., PVN or NTS) and the silver grain area overlying the
region were measured (NIH Image software, version 1.62) and are pre-
sented as grain area/brain area (mm2/mm2). Backgroundmeasurements
were made over areas adjacent to the region of interest and subtracted.
(2) The number of cells positively hybridized in a particular brain region
was counted manually in emulsion-dipped sections. A positive cell was
defined as one with more overlying silver grains than the mean over 10
cells lateral to the region of interest (background)  3 SDs. Data are
presented as the number of positive cells per brain area (mm2). (3) Grain
density per cell data were determined by measuring the silver grain area
over 240 cells per area per rat (Openlab version 2 software; Improvi-
sion). Backgroundmeasurementsweremade over equivalently sized cells
in the neuropil adjacent to the region of interest and subtracted. In each
case, measurements were made over a minimum of 12 PVN or NTS
profiles (bilateral measurements in six consecutive sections). Integrated
density was calculated by multiplying the mean number of positive neu-
rons in a specific brain region section by themean grain area per cell (data
given in arbitrary units). For all ISH measurements, average values for
each rat were used to calculate group means SEM.
Enzyme assays and thin-layer chromatography. Brain tissue was
weighed, and a 10% (w/v) homogenate (12.5 mg protein/ml) was pre-
pared in buffer, pH 7.22, containing 100mM potassium phosphate, 1mM
EDTA, and 0.32 M sucrose using a glass homogenizer. Protein concen-
tration of the homogenates was measured using the Bradford protein
assay. Homogenates were preincubated at 37°C for 10 min in 100 mM
potassium phosphate buffer containing 50 M EDTA, 5 mM dithiothre-
itol, and the appropriate cofactor (100MNADPH for 5-reductase and
100 M NADPH and 100 M NADH for 3-HSD) before addition of 20
Ci [1,2,6,7- 3H(N)]-progesterone (specific activity, 115Ci/mmol). The
Table 1. Oligonucleotide probe sequences for specific mRNA hybridization
Probe Length Sequence
CRH 42-mer 5-CCT GTT GCT GTG AGC TTG CTG AGC TAA CTG CTCTGC CCT GCC-3
pENK-A 39-mer 5-TGC ATC CTT CTT CAT GAA ACC GCC ATA CCT CTTGGC AAG-3
POMC 45-mer 5-CAT GAA GCC GCC GTA GCG CTT GTC CTT GGG CGGGTT GCC CCA GCG-3
-OR 45-mer 5-GAA ACC AGA GCC TCC CAC ACA CCC TGA CAG CAACCT GAT TCC ACG-3
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preparations were incubated in a shaking water
bath for 40min at 37°C. Control reactions were
included for each assay and contained all of the
components (given above) except for the tissue
homogenate. The reaction was terminated by
transferring the tubes to ice and by the addition
of ice-cold methanol/chloroform (1:1). Tubes
were agitated for 5min, and the different phases
were separated by centrifugation (6000 rpm for
1 min). Progesterone metabolites were sepa-
rated by thin-layer chromatography (TLC) us-
ing silica gel 60 F254 TLC plates (20  20 cm;
Merck) previously activated by heating at 100°C
for 15 min. Fifty microliters of each extract or
unlabeled standard [1 mg/ml (w/v) progester-
one, dihydroprogesterone, and allopreg-
nanolone in ethanol] were spotted onto the
bottom right-hand corner of the TLC plates.
Each plate was run in a two-dimensional sys-
tem: twice in solvent system 1 (benzene/meth-
anol, 19:1, v/v), then plates were turned 90o and
run twice in solvent system 2 (cyclohexane/
ethylacetate, 1:2, v/v). Steroids were visualized
by first exposing the TLC plates to 30% H2SO4
in ethanol, heating to 140°C for 15 min, and
then by ultraviolet illumination. The spots cor-
responding to the substrate (progesterone) and
metabolites were scraped from the plates and
the radioactivity counted in a -scintillation
counter. The quantity of the metabolites con-
verted from progesterone is expressed as a per-
centage of the total radioactivity and is indica-
tive of the enzyme activities.
Statistical analysis. SigmaStat (version 3.1;
Systat Software) and SPSS software (version 17;
SPSS) were used to analyze the data. The spe-
cific statistical tests used are given in Results.
Data from in situ hybridization studies and en-
zyme activity data were analyzed by ANOVA or
Student’s t test; when we had predicted direc-
tion of change, a one-tailed Student’s t test was
used. To analyze the effects of treatment across
time in plasma hormone data, two-way re-
peated measures ANOVA (two-way RM
ANOVA) (SigmaStat) were used when there
were two treatment groups. In cases in which
three ormore treatment groups were to be analyzed, a repeatedmeasures
mixed-model ANOVA (mixed ANOVA) (SPSS) was used, followed by a
two-way RM ANOVA to critically test our original hypotheses with
planned comparisons when appropriate. Specific differences were iso-
lated using Student–Newman–Keuls (SNK) multiple comparison post
hoc tests. In each case, values shown are group means  SEM. p values
0.05 were considered statistically significant.
Results
Effect of blocking allopregnanolone production on HPA axis
responses to IL-1
There was a significant effect of pregnancy (F(1,23)  12.0, p 
0.002, mixed ANOVA) and time (F(1,23) 43.7, p 0.0001) on
plasma ACTH responses to IL-1 (Fig. 1a). Within the virgin
groups (“virgin”), finasteride (“FIN”) treatment had no signifi-
cant effect on plasma ACTH concentration (F(1,84) 0.675, p
0.427, two-way RMANOVA), but there was a significant effect of
finasteride treatment within the pregnant groups (“preg”) (F(1,77)
 7.547, p 0.019, two-way RM ANOVA). Basal plasma ACTH
concentrations did not differ between virgin and pregnant rats
pretreated with vehicle (“veh”) or finasteride (Fig. 1a). IL-1
significantly increasedACTH secretion (3.2-fold; p 0.001, SNK
test) in the vehicle-pretreated virgin rats, but IL-1 had no sig-
nificant effect in the vehicle-pretreated pregnant rats ( p 0.839,
SNK test). Finasteride pretreatment had no effect on the ampli-
tude of the ACTH response to IL-1 in virgin rats. In late preg-
nant rats, finasteride significantly restored an ACTH response to
IL-1 ( p 0.002 vs basal levels, SNK test) to 77% at peak of that
observed in vehicle-treated virgin rats.
There was a significant effect of pregnancy (F(1,20) 6.0, p
0.023, mixed ANOVA) on plasma corticosterone concentrations
(Fig. 1b). Finasteride treatment had no significant effect on
plasma corticosterone concentration within the virgin groups
(F(1,44) 0.176, p 0.683, two-way RMANOVA), but there was
a significant effect of finasteride treatment within the pregnant
groups (F(1,42) 4.922, p 0.048). Basal plasma corticosterone
concentration was greater in the pregnant rats (this only reached
statistical significance in the preg/veh group; p 0.02, SNK test),
but finasteride treatment had no effect in either virgin or preg-
nant rats (basal plasma corticosterone concentrations: virgin/
veh, 50.1  5.3 ng/ml; virgin/FIN, 54.3  6.5 ng/ml; preg/veh,
159.9 27.6 ng/ml; preg/FIN, 120.4 17.5 ng/ml). As expected,
IL-1 significantly increased plasma corticosterone concentra-
Figure1. Effect of inhibiting allopregnanolone synthesis on HPA axis responses to IL-1 in virgin and pregnant rats. Virgin and
day 21 pregnant (preg) rats were treated with either finasteride (FIN; 25 mg/kg, s.c.) or vehicle (veh) 20 and 2 h before IL-1. After
two basal (B) blood samples (at t31 and1 min), all rats were administered IL-1 (500 ng/kg, i.v.) at t0 min. Additional
blood samples were taken 15, 30, 60, 90, and 120 min after treatment. Trunk blood was collected at t 240 min. n 6 –7 rats
per group. a, Plasma ACTH concentration. *p 0.03 versus basal values in the same group; #p 0.05 versus all other groups at
the same time point. b, Plasma corticosterone concentration. *p 0.04 versus basal values in the same group; #p 0.04 versus
preg/veh group at the same time point. Rats were killed 4 h after IL-1 administration, and brains were processed by in situ
hybridization. c, Quantification of CRH mRNA expression in the pPVN. CRH mRNA expression levels [expressed as arbitrary units
(a.u.)] were achieved by multiplying the grain density per neuron by the number of neurons positively expressing CRH mRNA.n
5–7 rats per group. *p 0.001 versus virgin/veh group; #p 0.003 versus virgin/FIN group; p 0.05 versus preg/veh group.
Values are group means  SEM. d, CRH mRNA: representative dark-field autoradiographs of coronal PVN sections from the
following: i, virgin/vehicle; ii, virgin/FIN; iii, pregnant/vehicle; and iv, pregnant/FIN. 3V, Third ventricle. Scale bar, 200m.
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tions in the vehicle-treated virgin but not pregnant rats (Fig. 1b)
( p  0.001, SNK test). Finasteride pretreatment had no signifi-
cant effect on the corticosterone response to IL-1 in the virgin
rats, but it resulted in a significant corticosterone response in the
late pregnant rats (Fig. 1b).
Treatment with finasteride alone (i.e.,
no IL-1) had no significant effect on
basal CRHmRNA expression in the pPVN
of late pregnant rats (grain area per pPVN
was 0.055  0.013 mm2/mm2 in vehicle-
treated rats, n 6 vs 0.050 0.019 mm2/
mm2 in finasteride-treated rats, n 4; p	
0.05, two-tailed Student’s t test). There
was, however, a significant effect of both
pregnancy (F(1,18) 34.5, p 0.001, two-
way ANOVA) and finasteride treatment
(F(1,18)  7.3, p  0.015) on CRH mRNA
expression in the pPVN after IL-1 ad-
ministration. In vehicle-treated pregnant
rats, CRH mRNA expression in the pPVN
was significantly less 4 h after systemic
IL-1 than in the vehicle-treated virgin
group (Fig. 1c,d). Finasteride had no effect
on CRH mRNA expression after IL-1 in
the virgin rats, but it resulted in a signifi-
cant increase in expression in the late preg-
nant rats (Fig. 1c,d).
Effect of allopregnanolone treatment on
HPA axis responses to IL-1
There was a significant effect of allopreg-
nanolone treatment (F(1,66)  13.2, p 
0.003, two-way RM ANOVA) on ACTH
secretion in the virgin rats (Fig. 2a). There
was no difference in basal plasma ACTH
concentration between vehicle and
allopregnanolone-pretreated virgin rats
(Fig. 2a). IL-1 significantly increased
ACTH secretion within 15min in both the
vehicle-treated virgins (4.0-fold increase;
p  0.001, SNK test) and the allopreg-
nanolone treated virgins (2.0-fold in-
crease; p  0.001); however, the response
was markedly reduced in the
allopregnanolone-treated group (57% of
the peak response in the vehicle group; p
0.001).
There was also a significant effect of al-
lopregnanolone treatment on corticoste-
rone secretion in the virgin rats (F(1,51) 
5.1, p  0.028, two-way RM ANOVA)
(Fig. 2c). Consistent with the ACTH data,
basal corticosterone secretion was not sig-
nificantly different between the vehicle-
and allopregnanolone-treated virgins (Fig.
2c), but the IL-1-evoked increase in cor-
ticosterone secretion was significantly at-
tenuated in the allopregnanolone-treated
group (Fig. 2c).
In the late pregnant rats, there was a
significant effect of drug treatment (F(1,58)
 6.2, p  0.034, two-way RM ANOVA)
on plasma ACTH concentration (Fig. 2b).
Neither finasteride alone nor combined finasteride and allopreg-
nanolone treatment affected basal plasma ACTH concentration
in late pregnant rats (Fig. 2b). As before, blocking allopreg-
nanolone production with finasteride restored a significant
ACTH response to IL-1 in late pregnant rats (Fig. 2b). This
Figure 2. Effect of allopregnanolone treatment on HPA axis responses to IL-1. Virgin rats (a, c, e) were treated with allo-
pregnanolone (3 and 1 mg/kg, s.c., 20 and 2 h before IL-1, respectively) or vehicle (veh), whereas pregnant (day 20 –21) rats (b,
d, f) were treated with finasteride (25 mg/kg, s.c.) and either allopregnanolone (as above) or vehicle 20 and 2 h before IL-1. After
two basal (B) blood samples (at t31 and1 min), all rats were administered IL-1 (500 ng/kg, i.v.) at t0 min. Additional
blood samples were taken 15, 30, 60, 90, and 120 min after treatment. Trunk blood was collected at t 240 min. Plasma ACTH
concentrations in virgin (a) and pregnant (b) rats. c, d, Plasma corticosterone concentrations in virgin (c) and pregnant (d) rats.
n 5–7 rats per group. a, *p 0.03 versus basal values in the same group; #p 0.04 versus virgin/veh group; b, *p 0.05
versus basal values in the same group; #p 0.001 versus preg/FIN/AP group; c, d, *p 0.001 versus basal values in the same
group; #p 0.04 versus other group at the same time point. Rats were killed 4 h after IL-1 administration, and brains were
processed by in situ hybridization. e, f, Quantification of CRH mRNA expression in the pPVN in brains from virgin (e) and pregnant
(f) rats. Grain density per pPVN profile [expressed as arbitrary units (a.u.)] was calculated by multiplying the mean grain density
per neuron by the mean number of neurons positively expressing CRH mRNA. n 6 –9 rats per group. e, *p 0.001 versus
virgin/AP group; f, *p 0.02 versus preg/FIN/AP group. All values are group means SEM.
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effect was prevented in the pregnant rats
by coadministration of allopregnanolone.
There was a significant effect of drug
treatment (F(1,40)  20.6, p  0.002, two-
way RM ANOVA) on corticosterone se-
cretion in the pregnant rats. Accordingly,
finasteride treatment restored a corticoste-
rone response to IL-1 in late pregnant
rats (Fig. 2d), which was attenuated by
combined allopregnanolone treatment.
CRH mRNA expression in the pPVN
4 h after systemic IL-1 was significantly
less in virgin rats pretreated with allo-
pregnanolone compared with those pre-
treated with vehicle (Fig. 2e) ( p 0.001,
one-tailed Student’s t test). Further-
more, CRH mRNA expression in the
pPVN 4 h after systemic IL-1 was sig-
nificantly less in pregnant rats treated
with a combination of finasteride and al-
lopregnanolone compared with preg-
nant rats treated with finasteride alone
(Fig. 2f ) ( p 0.01). Treatment of virgin
rats with allopregnanolone only for 20 h
had no effect on basal CRH mRNA ex-
pression in the pPVN (Table 2).
Effect of progesterone or
dihydroprogesterone on HPA axis
responses to IL-1 in virgin rats
As expected, subcutaneous progesterone
injections significantly increased plasma
progesterone concentrations (before in-
jection, 11.9 1.1 ng/ml vs after injection,
54.6 7.5 ng/ml; F(1,22) 18.3, p 0.001,
two-way RM ANOVA). There was no sig-
nificant effect of progesterone treatment
on either plasma ACTH (Fig. 3a) or corti-
costerone concentrations (Fig. 3b), but
there was a significant effect of IL-1 ad-
ministration on ACTH (F(7,56) 11.4, p
0.001) and corticosterone (F(5,39)  9.6,
p  0.001) secretion. Systemic IL-1 sig-
nificantly increased both plasma ACTH
(Fig. 3a) and corticosterone (Fig. 3b) con-
centrations compared with basal levels in
the vehicle- and progesterone-treated rats,
but there were no differences between
groups. Furthermore, progesterone pre-
treatment had no significant effect on
CRHmRNA expression in the pPVN after IL-1 (grain area was
0.27 0.03mm2/mm2 in the vehicle group vs 0.26 0.03mm2/
mm2 in the progesterone group; p 0.757, two-tailed Student’s
t test).
DHP treatment had no significant effect on either plasma
ACTH (Fig. 3c) or corticosterone (Fig. 3d) concentrations, but
IL-1 administration did have a significant effect (two-way RM
ANOVA: ACTH, F(7,71) 18.4, p 0.001; corticosterone, F(5,47)
 5.7, p  0.001). IL-1 increased plasma ACTH (Fig. 3c) and
corticosterone (Fig. 3d) concentrations similarly in the vehicle-
and DHP-treated virgin rats. As with progesterone, DHP treat-
ment had no significant effect on CRH mRNA expression in the
pPVN after IL-1 (grain area was 0.20 0.03 mm2/mm2 in the
vehicle group vs 0.29 0.04 mm2/mm2 in the DHP group; p
0.08, two-tailed Student’s t test).
Central expression of mRNA for the progesterone converting
enzymes in late pregnancy
Both 5-reductase and 3-HSD are expressed in white matter
(Melcangi et al., 1990; Lauber and Lichtensteiger, 1996). There
was no difference in mRNA expression for either enzyme in the
pyramidal tract [grain area (m2/m2): 5-reductase mRNA,
66.6  8.3 in virgin rats vs 74.2  14.1 in day 21 pregnant rats,
p	 0.05; 3-HSDmRNA, 8.9 1.2 in virgin rats vs 8.2 0.7 in
day 21 pregnant rats, p 	 0.05 two-tailed Student’s t test; n  6
per group]. There was no difference in 5-reductase mRNA ex-
Table 2. Virgin rats were treated with AP (3 and 1mg/kg, s.c.) or veh at t20 and2 h and then killed by
conscious decapitation at t 0 h (n 6–7 rats per group).
mRNA Brain region
Vehicle AP
# Positive cells Grain density per cell (m2) # Positive cells Grain density per cell (m2)
pENK-A NTS A2 115 3 34.0 0.3 141 10* 38.4 0.9**
pENK-A mgPVN 21.8 4.9 45.1 1.0 17.5 3.6 45.6 1.0
pENK-A Arc 46.5 4.5 30.6 0.5 51.2 1.3 30.9 0.4
POMC Arc 46.8 2.7 19.0 0.4 47.0 1.9 18.9 0.4
MOR NTS A2 117.1 12.2 19.2 0.6 108.5 7.5 18.6 0.7
CRH pPVN 131.1 11.7 49.3 6.6 131.1 6.9 44.6 3.5
mg PVN, Magnocellular subdivision of the paraventricular nucleus; Arc, arcuate nucleus. *p 0.02, **p 0.001 versus veh group. Values are mean SEM.
Figure 3. Effect of progesterone or dihydroprogesterone treatment on HPA axis responses to IL-1 in virgin rats. a, b, Virgin
rats were treated with either progesterone (prog; 20 and 4 mg/kg, s.c., 20 and 2 h before IL-1, respectively) or vehicle 20 and 2 h
before IL-1. c,d, In a separate experiment, rats were treated with DHP (4 and 1 mg/kg, s.c., 20 and 2 h before IL-1, respectively)
or vehicle (veh) 20 and 2 h before IL-1. After two basal blood samples (B; at t31 and1 min), all rats were administered
IL-1 (500 ng/kg, i.v.), and additional blood samples were withdrawn 15, 30, 60, 90, and 120 min after treatment. n 5– 8 rats
per group. Values are group means SEM. Plasma ACTH concentration (a) and plasma corticosterone concentration (b) before
and after systemic IL-1 in vehicle- and progesterone-treated virgin rats. Plasma ACTH concentration (c) and plasma corticoste-
rone concentration (d) before and after systemic IL-1 in vehicle- and DHP-treated virgin rats. *p 0.05 versus basal.
6454 • J. Neurosci., May 20, 2009 • 29(20):6449 – 6460 Brunton et al. • Allopregnanolone and HPA Axis in Pregnancy
pression in the PVN between virgin and late pregnant rats (Fig.
4a), but 5-reductase mRNA levels were significantly greater in
the A2 region of the NTS of the late pregnant group compared
with the nonpregnant group (Fig. 4b,f) ( p  0.047, one-tailed
Student’s t test). There was a modest but significant increase in
3-HSDmRNAexpression in the PVN in late pregnant rats com-
pared with virgin rats (Fig. 4c,e) ( p  0.042), but a significant
difference in the level of 3-HSD mRNA expression in the A2
region of the NTS was not detected between virgin and pregnant
rats (Fig. 4d) ( p 0.069).
Activity of the progesterone converting enzymes in the brain
in late pregnancy
5-Reductase activity was significantly greater in the hypothala-
mus in late pregnant rats compared with virgin rats ([3H]proges-
terone conversion into DHP was 2.6 0.5% in the virgin group,
n 8 vs 5.6 0.8% in the late pregnant group, n 6; p 0.033,
one-tailed Student’s t test). 3-HSD activity also tended to be
greater in the hypothalamus in pregnant rats, but this was not
statistically significant ([3H]progesterone conversion into AP
was 0.3 0.1% in the virgin group, n 8 vs 0.7 0.3% in the late
pregnant group, n 6; p 0.07). No difference was detected in
the activities of either enzyme in the medulla oblongata
([3H]progesterone conversion into DHP was 2.6  0.7% in the
virgin group vs 3.2 0.8% in the late pregnant group, p	 0.05;
[3H]progesterone conversion into AP was 0.3  0.1% in the
virgin group vs 0.4 0.1% in the late pregnant group, p	 0.05).
Effect of blocking allopregnanolone synthesis and
endogenous opioid action on HPA axis responses to IL-1 in
late pregnant rats
There was a significant effect of finasteride (F(1,20)  13.9, p 
0.001, mixed ANOVA) and naloxone (F(1,20)  4.4, p  0.048)
treatment on ACTH responses to IL-1 in the late pregnant
groups (Fig. 5a). Neither finasteride nor naloxone altered basal
plasma ACTH concentration in virgin or pregnant rats (Fig. 5a).
IL-1 significantly increased plasma ACTH concentration (3.2-
fold increase) (Fig. 5a,b) in the vehicle-pretreated virgin rats but
had no significant effect in the vehicle-pretreated pregnant rats
(Fig. 5a,b). Both finasteride only and naloxone only pretreatment
restored an ACTH response to IL-1 in the late pregnant rats to
71 and 65% of the response observed in the virgin controls, re-
spectively (Fig. 5a,b). However, combined finasteride and nalox-
one pretreatment had no additional effect on the ACTH response
to IL-1 in late pregnant rats compared with either naloxone or
finasteride treatment alone (Fig. 5a,b). In a separate experiment,
naloxone (5 mg/kg, i.v., with no subsequent IL-1 treatment)
had no effect on plasma ACTH concentration over a 90 min
period in either virgin or late pregnant rats (Fig. 5c) ( p 	 0.05,
mixed ANOVA).
Plasma corticosterone concentrations before IL-1 adminis-
tration were as follows: virgin/oil/saline, 106.6  11.5 ng/ml;
pregnant/oil/saline, 121.4  8.9 ng/ml; pregnant/oil/naloxone,
129.2 10.1 ng/ml; pregnant/finasteride/saline, 107.0 9.7 ng/
ml; pregnant/finasteride/naloxone, 117.4 8.9 ng/ml. There was
an overall effect of drug treatment (F(4,158)  4.6, p  0.006,
two-way RM ANOVA) on corticosterone responses to IL-1.
IL-1 significantly increased plasma corticosterone concentra-
tion in the vehicle-treated virgin but not pregnant rats (Fig. 5d,e).
Pretreatment with finasteride alone, naloxone alone, or com-
bined finasteride and naloxone all restored corticosterone re-
sponses to IL-1 in the pregnant groups, with no significant dif-
ferences between groups or compared with the vehicle-treated
virgin rats (Fig. 5d,e).
There was a significant effect of pregnancy status (F(1,31) 
25.9, p 0.001, two-way ANOVA) and drug treatment (F(3,31)
5.0, p 0.006) on CRHmRNA expression. CRHmRNA expres-
sion in the pPVN 4 h after systemic IL-1was significantly less in
vehicle-pretreated pregnant rats than in vehicle-treated virgin
rats (Fig. 5f). Pretreatment with finasteride alone, naloxone
alone, or combined finasteride and naloxone all resulted after
Figure4. Central expression of mRNA for the progesterone converting enzymes in late preg-
nancy. Virgin and day 21 pregnant rats were killed by conscious decapitation, and brains were
processed by in situ hybridization using 35S-labeled riboprobes complementary to rat 5-
reductase mRNA and rat 3-HSD mRNA.a,b, Quantification of 5-reductase mRNA expression
in the PVN (a) and 5-reductase mRNA expression in the A2 region of the NTS (b). Data are
expressed as the grain area per PVN (mm 2/mm 2) or NTS (m 2/m 2) profile. *p 0.05
versus virgin group. c, d, Quantification of 3-HSD mRNA in the PVN (c) and 3-HSD mRNA
expression in the A2 region of the NTS (d). Data are expressed either as mean grain density/PVN
[expressed as arbitrary units (a.u.); the mean grain density per neuron times number of neurons
positively expressing 3-HSD mRNA) or as grain area per NTS profile (m 2/m 2).] *p 0.05
versus virgin group. n 5– 6 rats per group. All values are group means SEM. e, Representative
photomicrographs of 3-HSD mRNA expression in the PVN of virgin (i) and pregnant (ii) rats. Higher-
magnification views of the areas indicated by the dashed box are shown from virgin (iii) and pregnant
(iv) rats. 3V, Third ventricle. Scale bars: top, 200m; bottom, 100m. Filled arrows indicate positive
cells. f, Representative photomicrographs of 5-reductase mRNA expression in the A2 region of the
NTS from virgin (i) and pregnant (ii) rats. Scale bar, 100m.
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IL-1 in similar levels of CRHmRNA expression in the pPVN of
late pregnant rats that were significantly greater than in the
vehicle-treated pregnant group (Fig. 5f). Naloxone alone (i.e., no
subsequent IL-1 treatment) had no effect after 4 h on basal CRH
mRNA expression in the pPVN (same rats as in Fig. 5c); the
mean  SEM number of CRH mRNA-expressing cells in the
pPVNwas as follows: virgin/saline, 228.1 13.4 (n 10); virgin/
naloxone, 221.2  12.2 (n  5); pregnant/saline, 176.5  16.4
(n 10); pregnant/naloxone, 176.6 18.3 (n 6). There was no
significant effect of naloxone on CRHmRNA in the virgin or the
pregnant rats ( p 	 0.05, two-way ANOVA), but there was an
effect of pregnancy (F(1,27) 8.3, p 0.008). As detailed above,
finasteride alone had no effect on CRHmRNA expression in the
pPVN of late pregnant rats.
Effect of allopregnanolone treatment on induction of inhibitory
opioid tone overHPAaxis responses to IL-1 in virgin rats
There was a significant effect of the allopregnanolone treatment
(F(1,109)  6.2, p  0.023, two-way RM ANOVA) within the
saline-treated rats on plasma ACTH concentrations (Fig. 6a).
Moreover, within the allopregnanolone-treated rats, there was a
significant effect of naloxone treatment (F(1,105)  4.0, p 
0.048). There was no difference in basal ACTH secretion among
vehicle- and allopregnanolone-pretreated virgin rats with or
without naloxone treatment (Fig. 6a). In the vehicle (oil)-
pretreated groups, IL-1 significantly increased plasma ACTH
concentration, with no effect of previous naloxone treatment
(Fig. 6a,b). As before (Fig. 2), IL-1 induced a significant increase
in ACTH secretion in the AP/saline-treated group (2.2-fold in-
crease), but the amplitude of the response was attenuated com-
pared with the virgin control group (3.8-fold increase) (Fig. 6b).
Moreover, the suppressive effect of AP on the ACTH response to
IL-1 was completely reversed in the presence of naloxone (Fig.
6a,b). Similarly, CRH mRNA expression in the pPVN 4 h after
IL-1 administration was less in the virgin rats treated with AP
alone compared with the controls (Fig. 6c) (F(1,36)  5.5, p 
0.025, two-way ANOVA). This effect of AP was reversed in rats
coadministered naloxone (Fig. 6c).
Effect of allopregnanolone treatment on central opioid gene
expression in virgin rats
Mimicking pregnancy in virgin rats with allopregnanolone treat-
ment significantly increased pENK-A mRNA expression in the
A2 region of the NTS (Fig. 7a,b) ( p 0.001, one-tailed Student’s
t test). This was a consequence of both an increase in the number
of neurons expressing pENK-A mRNA and an increase in the
Figure 5. Effect of inhibiting allopregnanolone synthesis and endogenous opioid action on HPA axis responses to IL-1 in late pregnancy. Day 21 pregnant (preg) rats were treated with either
finasteride (FIN; 25 mg/kg, s.c.) or vehicle (oil) 20 and 2 h before IL-1. After a basal (B) blood sample (at t31 min), rats were administered naloxone (NLX; 5 mg/kg, i.v.) or vehicle [saline (sal);
0.5 ml/kg, i.v.]. Two additional blood samples were collected at16 and1 min, after which all rats were administered IL-1 (500 ng/kg, i.v.) at t 0 min. Additional blood samples were taken
15, 30, 60, 90, and 120 min after treatment. Trunk blood was collected at t 240 min. A group of virgin rats pretreated with vehicle (oil) and then saline before IL-1 administration was included
for comparison. a, b, Plasma ACTH concentration (a) and increase in ACTH secretion (b) from basal levels 30 min after IL-1. c, Plasma ACTH concentration in a separate group of virgin and day 21
pregnant (preg) rats before and after treatment only with naloxone (NLX; 5 mg/kg, i.v.) or saline (0.5 ml/kg, i.v.) administration. No significant differences within or between groups were detected.
d, e, Plasma corticosterone concentration (d) and increase in corticosterone secretion (e) from basal levels 30 min after IL-1 from the same rats shown ina andb. n 6 –7 rats per group.a, *p
0.04 versus basal values in the same group; #p 0.04, p 0.007 versus all other groups at the same time point; b, *p 0.001 versus all other groups; d, *p 0.009 versus basal values in the
same group; #p 0.008 versus all other groups at the same time point; p 0.02 versus preg/FIN/NLX group. e, *p 0.05 versus all other groups. Rats were killed 4 h after IL-1 administration,
and brains were processed by in situ hybridization. f, Quantification of CRH mRNA expression in the pPVN. n 6 – 8 rats per group. f, *p 0.05, #p 0.001 versus preg/oil/saline group. All values
are group means SEM.
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levels of expression per neuron (Table 2). Allopregnanolone
treatment had no significant effect on pENK-A mRNA expres-
sion in the pPVN, magnocellular division of the PVN or the
arcuate nucleus (Table 2). There were also no significant differ-
ences in POMC mRNA expression in the arcuate nucleus or
-opioid receptormRNA expression in theNTS (Table 2). In late
pregnant rats, 20 h finasteride treatment resulted in a significant
reduction in pENK-A mRNA expression in the A2 region of the
NTS (Fig. 7c) ( p 0.003).
Discussion
Our results demonstrate that allopregnanolone restrains HPA
axis responses to immune challenge in late pregnancy and impli-
cate mediation of allopregnanolone actions by activation of en-
dogenous opioid expression in the NTS.
Role of allopregnanolone
HPA responses to IL-1 were suppressed in late pregnancy as
found previously (Brunton et al., 2005). Blocking allopreg-
nanolone production with finasteride [previously shown to de-
crease cortical allopregnanolone content by 90% (Concas et al.,
1998)] restored HPA axis responses to
IL-1 in pregnant rats, reflected by in-
creased CRH mRNA expression in the
pPVN, and ACTH and corticosterone se-
cretion, whereas concurrent allopreg-
nanolone treatment prevented these finas-
teride effects. Furthermore, we mimicked
reduced pregnancy-type HPA axis re-
sponses to IL-1 in nonpregnant rats with
short-term (2–20 h) allopregnanolone
treatment. Central effects were shown
because, in pregnant rats finasteride en-
hanced and in virgin rats allopreg-
nanolone treatment reduced the in-
crease in pPVN CRH mRNA expression
after systemic IL-1. These treatments
did not affect basal pPVN CRH mRNA
expression or basal plasma ACTH or
corticosterone concentrations. Hence,
the neurosteroid manipulations specifi-
cally altered HPA responses to the sys-
temic IL-1 challenge.
Systemic IL-1 activates pPVN CRH neurons via brainstem
noradrenergic A2 neurons (Rivest et al., 2000) but is ineffective in
late pregnancy (Brunton et al., 2005). It is unclear where in the
brain allopregnanolone acts to exert its suppressive effects on
HPA responses to IL-1. Allopregnanolone may prevent stimu-
lation of CRH neurons in the PVN by noradrenaline (Patchev et
al., 1994) or it may inhibit CRH neurons by modulating GABA
inputs to the PVN by its actions on GABAA receptors. For exam-
ple, GABA neurons in the peri-PVN area mediate glucocorticoid
negative feedback (Di et al., 2009), whereas GABA neurons in the
bed nucleus of stria terminalis (Cullinan et al., 2008) can modu-
late HPA responses to IL-1 (Crane et al., 2003).
The NTS contains intrinsic GABA neurons (Fong et al., 2005;
Bailey et al., 2008), GABA-containing terminals, and GABAA re-
ceptor subunits (Terai et al., 1998; Saha et al., 2001), and GABA
release in the NTS is increased by depolarization (Sved and Cur-
tis, 1993). Effects of GABA onNTS neurons identified as project-
ing to the PVN are not reported, nonetheless GABA inhibits the
electrical activity of A2 neurons (Moore and Guyenet, 1983) and
Figure 6. Effect of allopregnanolone treatment on induction of inhibitory opioid tone over HPA axis responses to IL-1 in virgin rats. Virgin rats were treated with allopregnanolone (3 and 1
mg/kg, s.c., 20 and 2 h before IL-1, respectively) or vehicle (oil). After a basal (B) blood sample (at t31 min), rats were administered naloxone (NLX; 5 mg/kg, i.v.) or vehicle [saline (sal); 0.5
ml/kg, i.v.]. Two additional blood samples were collected at16 and1 min, after which all rats were administered IL-1 (500 ng/kg, i.v.) at t 0 min. Additional blood samples were taken 15,
30, 60, 90, and 120 min after treatment. Trunk blood was collected at t 240 min. a, b, Plasma ACTH concentration (a) and increase in ACTH secretion (b) from post-naloxone levels 15 min after
IL-1. n 8 –10 rats per group. a, *p 0.05 versus basal values in the same group; #p 0.04 versus AP/sal group; b, *p 0.05 versus AP/sal group. Rats were killed 4 h after IL-1
administration, and brains were processed by in situ hybridization. c, CRH mRNA expression in the pPVN. Quantification by in situ hybridization 4 h after intravenous IL-1, expressed as number of
neurons expressing CRH mRNA per unit area pPVN. n 8 –13 rats per group. *p 0.04 versus AP/saline group. All values are group means SEM.
Figure 7. Effect of allopregnanolone and finasteride on opioid mRNA expression in NTS. a, pENK-A mRNA expression in the A2
region of the NTS in virgin rats treated with AP (3 and 1 mg/kg, s.c.) or vehicle (veh) at t20 and2 h. Brains were collected
at t 0 h. *p 0.001 versus vehicle group. Grain density per NTS [in arbitrary units (a.u.)] is the number of positive cells per NTS
section times grain density per cell. b, Representative photomicrographs of pENK-A mRNA in the A2 region of the NTS from
vehicle-treated virgin (i) and AP-treated virgin (ii) rats. APo, Area postrema; CC, central canal; 10, dorsal motor nucleus of vagus;
12, hypoglossal nucleus. Scale bars: top, 100 m; bottom, 25 m. Vehicle-treated virgin (iii) and AP-treated virgin (iv) rats;
higher-magnification views are indicated by the dashed box. c, pENK-A mRNA expression in the A2 region of the NTS in day 21
pregnant rats treated with finasteride (FIN; 25 mg/kg, s.c.) or vehicle (veh) at t20 and2 h. Brains were collected at t0 h. *p
0.01 versus veh group. Grain density was calculated as above.n 5–7 rats per group. All values are group means SEM.
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GABA injected into the NTS inhibits noradrenaline release in the
subfornical organ (Tanaka et al., 2002). Moreover, GABA neu-
rons can express 5-reductase and 3-HSD (Agís-Balboa et al.,
2006). Hence, in late pregnancy, allopregnanolone might en-
hance GABA action at the PVN, or on its inputs, including in the
NTS, to attenuate HPA axis stress responses.
Allopregnanolone-synthesizing enzymes
Neither of the allopregnanolone precursors progesterone nor
DHP reduced HPA responses to IL-1 in virgin rats, indicating
ineffective conversion to allopregnanolone. In contrast, in the
NTS in late pregnancy, 5-reductase (the rate-limiting enzyme)
mRNA expression was increased, and 3-HSD mRNA levels
tended to increase ( p  0.07). Metabolism of progesterone by
5-reductase and 3-HSD in the medulla has been described
previously (Hanukoglu et al., 1977), but we found no change
in pregnancy. Levels of 3-HSDmRNA (but not 5-reductase
mRNA) were increased in the PVN in late pregnancy. Further-
more, 5-reductase activity was increased (whereas 3-HSD
activity tended to increase) in the hypothalamus in late preg-
nancy. Together, these data indicate increased allopreg-
nanolone generation in late pregnancy in brain regions in-
volved in stressor processing.
Discrepancies between enzyme mRNA levels and activity
changes in pregnancy likely reflect the highly localized mRNA
measurements (PVN and NTS), whereas activity measurements
were made in whole hypothalamus and medulla. Increased allo-
pregnanolone production by the NTS would be obscured by the
predominance of elements such as the pyramidal tracts with
abundant 5-reductase activity (Melcangi et al., 1988), in which
we found no changes in mRNA expression in pregnancy. None-
theless, increased 5-reductase mRNA (and 3-HSD mRNA)
expression in the NTS in late pregnancy is expected to lead to
increased allopregnanolone generation for local action on A2
neurons, presumptively via GABAA receptors. It is worth noting
that allopregnanolone can also act via progesterone receptors
after intracellular conversion to 5-DHP (Rupprecht, 2003), but
because few A2 cells express progesterone receptor in pregnancy
(Francis et al., 2002), it is unlikely allopregnanolone exerts its
actions in the NTS through these receptors.
Presumably, increased activity of the central synthesizing en-
zymes contributes to the increased brain content of allopreg-
nanolone in pregnancy (Concas et al., 1998), although peripheral
production is also likely to be a factor. 5-Reductase and 3-HSD
are highly expressed in liver (Pirog and Collins, 1994; Torres and
Ortega, 2004), but changes in rat pregnancy are not known. In the
mouse, 5-reductase mRNA in the liver is increased duringmid-
pregnancy, whereas the placenta expresses little after day 10 (Ma-
hendroo et al., 1997).
5-Reductase and 3-HSD also metabolize 11-deoxycor-
ticosterone (DOC), from the adrenal cortex, to 3,5-tetra-
hydrodeoxycorticosterone (TH-DOC), a neurosteroid acting like
allopregnanolone (Womack et al., 2006). DOC secretion is in-
creased by acute stress (Reddy and Rogawski, 2002a), but finas-
teride actions via decreased TH-DOC formation in the current
study are unlikely because corticosterone levels in pregnant rats
were no greater than in virgins.
Regulation of 5-reductase and 3-HSD
The factor(s) responsible for regulating central expression of 5-
reductase and 3-HSD are unclear. Putative candidates are sex
steroids, but to date, neither estrogen nor progesterone is known
to regulate 5-reductase type 1 expression in the brain. 3-HSD
activity in the hypothalamus can be regulated by ovarian hor-
mones (Bertics et al., 1987), and estrogen, but not progesterone,
can increase hippocampal 3-HSD mRNA expression (Mitev et
al., 2003).
5-Reductase gene expression in the female forebrain is stim-
ulated by dihydrotestosterone (Torres and Ortega, 2006); how-
ever, whether other 5-reduced steroids, such as allopreg-
nanolone can regulate expression, is not known. In pregnancy,
increased levels of prolactin may play a role in upregulating 5-
reductase gene expression in the forebrain (Sa´nchez et al., 2008).
Endogenous opioids
Reduced HPA responses to IL-1 in late pregnancy involve opi-
oid inhibition of noradrenaline release in the PVN, potentially by
met-enkephalin coproduced in NTS neurons projecting to the
PVN (Beaulieu et al., 1996), because NTS pENK-A and MOR
mRNA expression increase in late pregnancy (Brunton et al.,
2005). Here, combined finasteride and naloxone treatment had
no greater effect in restoring HPA axis responses to IL-1 in late
pregnancy than either drug alone. Finasteride and naloxone,
alone or combined, fully restored the corticosterone profile but
not the ACTH levels to the virgin values. Enhanced sensitivity to
ACTH as a result of high estrogen levels in pregnancy can explain
such lack of fidelity between the ACTH and corticosterone re-
sponses (Figueiredo et al., 2007). The capacity of the anterior
pituitary to generate anACTHresponse to stress is not reduced in
late pregnancy (Ma et al., 2005), indicating that some central
HPA elements remain hypoactive even after finasteride and nal-
oxone treatment. Nonetheless, lack of additive effects of finas-
teride and naloxone indicated interlinked allopregnanolone and
opioid mechanisms. Indeed, allopregnanolone induced opioid
inhibition over HPA axis responses to IL-1 in virgin rats. More-
over, allopregnanolone treatment for 20 h upregulated pENK-A
mRNA expression in the NTS of virgin rats by 35%, consistent
with the 31% increase reported in late pregnancy (Brunton et al.,
2005). Furthermore, finasteride reduced pENK-AmRNAexpres-
sion in the NTS of late pregnant rats, likely explaining how finas-
teride restores HPA axis responses to IL-1.
Regulation of opioid expression in the NTS by allopreg-
nanolone might involve interaction with GABAA receptors, but
such action inhibits PVN oxytocin mRNA expression (Blyth et
al., 2000) and direct GABAA receptor activation inhibits pPVN
pENK-A, CRH, and vasopressin mRNA expression (Borsook et
al., 1999; Bali and Kova´cs, 2003).
Changes in pENK-AmRNA expression in the NTS after treat-
ment with allopregnanolone in virgins or finasteride in pregnant
rats were seen within 20 h. Rapid increases in pENK-A mRNA
expression have been described after acute stress in the NTS
(Boone andMcMillen, 1994) and in the pPVN (García-García et
al., 1998), which are dependent on increased corticosterone, at
least in the case of the PVN (García-García et al., 1998). Here, the
changes in pENK-A mRNA in the NTS were not related to basal
plasma corticosterone levels, because these were unaltered by
pregnancy or by allopregnanolone or finasteride treatment.
Allopregnanolone treatment did not alter MOR mRNA ex-
pression in the NTS, which is increased by day 10 of pregnancy
(Brunton et al., 2005). Upregulation of MOR may rely on in-
creased levels of circulating estrogen in pregnancy (Zhu andPfaff,
1995; Eckersell et al., 1998; Priest and Roberts, 2000).
It remains to be shown whether allopregnanolone induction
of pENK-A mRNA in the NTS leads to preterminal inhibition of
noradrenaline release in the pPVN after systemic IL-1 as in
pregnancy (Brunton et al., 2005).
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We conclude that the emergence and maintenance of endog-
enous opioid inhibition of HPA axis responses to stress in late
pregnancy depends on central actions of increased levels of allo-
pregnanolone. This novel allopregnanolone-induced opioid
mechanism may regulate other neuroendocrine mechanisms in
pregnancy (Brunton and Russell, 2008).
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